Clinical trial referrals don’t usually fail because patients aren’t interested. They fail because too many patients are pushed downstream before they’re truly qualified, informed, and ready for the next step. That creates a familiar pattern across studies: high referral volume, low referral quality, overloaded site teams, delayed enrollment, and preventable screening waste that gets blamed on recruitment alone. A recent 2025 oncology study helps frame the issue clearly. Across three cancer centers, screen-failure rates ranged from 21% to 26%. The most common causes were radiological, biological, and clinical. The authors concluded that getting key patient information earlier may help reduce unnecessary screen failures (Korakis et al., 2025). That is the real problem. Not just whether patients are entering the funnel, but whether the right patients are reaching the site with enough qualification and readiness to move forward. Read on to see how Antidote helps improve referral quality upstream before screen failures reach the site.